Literature DB >> 15749280

Mammalian carboxylesterases: from drug targets to protein therapeutics.

Matthew R Redinbo1, Philip M Potter.   

Abstract

Our understanding of the detailed recognition and processing of clinically useful therapeutic agents has grown rapidly in recent years, and we are now able to begin to apply this knowledge to the rational treatment of disease. Mammalian carboxylesterases (CEs) are enzymes with broad substrate specificities that have key roles in the metabolism of a wide variety of clinical drugs, illicit narcotics and chemical nerve agents. Here, the functions, mechanism of action and structures of human CEs are reviewed, with the goal of understanding how these proteins are able to act in such a non-specific fashion, yet catalyze a remarkably specific chemical reaction. Current approaches to harness these enzymes as protein-based therapeutics for drug and chemical toxin clearance are described, as well as their uses for targeted chemotherapeutic prodrug activation. Also included is an outline of how selective CE inhibitors could be used as co-drugs to improve the efficacy of clinically approved agents.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15749280     DOI: 10.1016/S1359-6446(05)03383-0

Source DB:  PubMed          Journal:  Drug Discov Today        ISSN: 1359-6446            Impact factor:   7.851


  65 in total

1.  Phospho-ibuprofen (MDC-917) incorporated in nanocarriers: anti-cancer activity in vitro and in vivo.

Authors:  T Nie; C C Wong; N Alston; P Aro; P P Constantinides; B Rigas
Journal:  Br J Pharmacol       Date:  2012-06       Impact factor: 8.739

2.  Reversible inhibitory effects of saturated and unsaturated alkyl esters on the carboxylesterases activity in rat intestine.

Authors:  Ping Li; Chun-Liu Zhu; Xin-Xin Zhang; Li Gan; Hong-Zhen Yu; Yong Gan
Journal:  Lipids       Date:  2010-06-08       Impact factor: 1.880

3.  Effects of aging on mRNA profiles for drug-metabolizing enzymes and transporters in livers of male and female mice.

Authors:  Zidong Donna Fu; Iván L Csanaky; Curtis D Klaassen
Journal:  Drug Metab Dispos       Date:  2012-03-23       Impact factor: 3.922

4.  Mammalian carboxylesterase 3: comparative genomics and proteomics.

Authors:  Roger S Holmes; Laura A Cox; John L VandeBerg
Journal:  Genetica       Date:  2010-04-28       Impact factor: 1.082

5.  Biochemical and molecular analysis of carboxylesterase-mediated hydrolysis of cocaine and heroin.

Authors:  M J Hatfield; L Tsurkan; J L Hyatt; X Yu; C C Edwards; L D Hicks; R M Wadkins; P M Potter
Journal:  Br J Pharmacol       Date:  2010-08       Impact factor: 8.739

Review 6.  Butyrylcholinesterase for protection from organophosphorus poisons: catalytic complexities and hysteretic behavior.

Authors:  Patrick Masson; Oksana Lockridge
Journal:  Arch Biochem Biophys       Date:  2009-12-11       Impact factor: 4.013

7.  Potent, Irreversible Inhibition of Human Carboxylesterases by Tanshinone Anhydrides Isolated from Salvia miltiorrhiza ("Danshen").

Authors:  M Jason Hatfield; Randall J Binder; Rowan Gannon; Ellie M Fratt; John Bowling; Philip M Potter
Journal:  J Nat Prod       Date:  2018-10-23       Impact factor: 4.050

8.  Carboxylate Surrogates Enhance the Antimycobacterial Activity of UDP-Galactopyranose Mutase Probes.

Authors:  Valerie J Winton; Claudia Aldrich; Laura L Kiessling
Journal:  ACS Infect Dis       Date:  2016-06-29       Impact factor: 5.084

9.  Human carboxylesterase 1 stereoselectively binds the nerve agent cyclosarin and spontaneously hydrolyzes the nerve agent sarin.

Authors:  Andrew C Hemmert; Tamara C Otto; Monika Wierdl; Carol C Edwards; Christopher D Fleming; Mary MacDonald; John R Cashman; Philip M Potter; Douglas M Cerasoli; Matthew R Redinbo
Journal:  Mol Pharmacol       Date:  2010-01-05       Impact factor: 4.436

10.  Baboon carboxylesterases 1 and 2: sequences, structures and phylogenetic relationships with human and other primate carboxylesterases.

Authors:  Roger S Holmes; Jeremy P Glenn; John L VandeBerg; Laura A Cox
Journal:  J Med Primatol       Date:  2009-02       Impact factor: 0.667

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.